Takese McKenzie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Takese McKenzie has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jian Hu
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, USA
2 shared publications Bridgitte E. Palacios
Department of Cancer Biology The University of Texas MD Anderson Cancer Center Houston TX USA
1 shared publication- Bridgitte E. Palacios
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, USA
1 shared publication Chang-Liang Peng
Department of Orthopaedics, The Second Hospital, College of Medicine, Shandong University, Jinan, China
1 shared publicationFeilong Chen
State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Protein Science, and College of Life Sciences, Nankai University, Tianjin, China
1 shared publication- Hao Zhou
Nankai University
1 shared publication
Latest Publications
- Open Access
Lipid-Laden Microglia: Characterization and Roles in Diseases
Microglia are resident phagocytes of the central nervous system that play an essential role in brain development and homeostasis. When the intracellular lipid content exceeds the metabolic capacity of microglia, lipid droplets accumulate, giving rise to a distinct population termed lipid-laden microglia (LLMs). LLMs have been implicated in various neuroinflammatory and neurodegenerative diseases, functioning as both regulators/indicators of inflammation and potential therapeutic targets. This review summarizes the current research on LLMs, focusing on disease-specific regulators and functions, protective roles, interactions with neighboring cells, and advances in diagnostic and analytical tools. We also discuss the blurred distinction between LLMs and macrophages, inconsistent terminology, and major knowledge gaps across different disease contexts. Deciphering the composition, formation, and dynamics of lipid droplets in microglia is critical for uncovering how microglial states shift under diverse pathological stimuli. A clearer view of these mechanisms may reveal novel roles of LLMs and open new avenues for therapeutic intervention.
Open AccessLipid-Laden Microglia: Characterization and Roles in Diseases
Microglia are resident phagocytes of the central nervous system that play an essential role in brain development and homeostasis. When the intracellular lipid content exceeds the metabolic capacity of microglia, lipid droplets accumulate, giving rise to a distinct population termed lipid-laden microglia (LLMs). LLMs have been implicated in various neuroinflammatory and neurodegenerative diseases, functioning as both regulators/indicators of inflammation and potential therapeutic targets. This review summarizes the current research on LLMs, focusing on disease-specific regulators and functions, protective roles, interactions with neighboring cells, and advances in diagnostic and analytical tools. We also discuss the blurred distinction between LLMs and macrophages, inconsistent terminology, and major knowledge gaps across different disease contexts. Deciphering the composition, formation, and dynamics of lipid droplets in microglia is critical for uncovering how microglial states shift under diverse pathological stimuli. A clearer view of these mechanisms may reveal novel roles of LLMs and open new avenues for therapeutic intervention.
- 22 June 2022
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 34 (7) , e13171
Nuclear hormone receptors in demyelinating diseases
Demyelination results from the pathological loss of myelin and is a hallmark of many neurodegenerative diseases. Despite the prevalence of demyelinating diseases, there are no disease modifying therapies that prevent the loss of myelin or promote remyelination. This review aims to summarize studies in the field that highlight the importance of nuclear hormone receptors in the promotion and maintenance of myelination and the relevance of nuclear hormone receptors as potential therapeutic targets for demyelinating diseases. These nuclear hormone receptors include the estrogen receptor, progesterone receptor, androgen receptor, vitamin D receptor, thyroid hormone receptor, peroxisome proliferator‐activated receptor, liver X receptor, and retinoid X receptor. Pre‐clinical studies in well‐established animal models of demyelination have shown a prominent role of these nuclear hormone receptors in myelination through their promotion of oligodendrocyte maturation and development. The activation of the nuclear hormone receptors by their ligands also promotes the synthesis of myelin proteins and lipids in mouse models of demyelination. There are limited clinical studies that focus on how the activation of these nuclear hormone receptors could alleviate demyelination in patients with diseases such as multiple sclerosis (MS). However, the completed clinical trials have reported improved clinical outcome in MS patients treated with the ligands of some of these nuclear hormone receptors. Together, the positive results from both clinical and pre‐clinical studies point to nuclear hormone receptors as promising therapeutic targets to counter demyelination.
- 22 June 2022
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 34 (7) , e13171
Nuclear hormone receptors in demyelinating diseases
Demyelination results from the pathological loss of myelin and is a hallmark of many neurodegenerative diseases. Despite the prevalence of demyelinating diseases, there are no disease modifying therapies that prevent the loss of myelin or promote remyelination. This review aims to summarize studies in the field that highlight the importance of nuclear hormone receptors in the promotion and maintenance of myelination and the relevance of nuclear hormone receptors as potential therapeutic targets for demyelinating diseases. These nuclear hormone receptors include the estrogen receptor, progesterone receptor, androgen receptor, vitamin D receptor, thyroid hormone receptor, peroxisome proliferator‐activated receptor, liver X receptor, and retinoid X receptor. Pre‐clinical studies in well‐established animal models of demyelination have shown a prominent role of these nuclear hormone receptors in myelination through their promotion of oligodendrocyte maturation and development. The activation of the nuclear hormone receptors by their ligands also promotes the synthesis of myelin proteins and lipids in mouse models of demyelination. There are limited clinical studies that focus on how the activation of these nuclear hormone receptors could alleviate demyelination in patients with diseases such as multiple sclerosis (MS). However, the completed clinical trials have reported improved clinical outcome in MS patients treated with the ligands of some of these nuclear hormone receptors. Together, the positive results from both clinical and pre‐clinical studies point to nuclear hormone receptors as promising therapeutic targets to counter demyelination.
- Open Access
- 18 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Phase transition and remodeling complex assembly are important for SS18-SSX oncogenic activity in synovial sarcomas
Oncoprotein SS18-SSX is a hallmark of synovial sarcomas. However, as a part of the SS18-SSX fusion protein, SS18’s function remains unclear. Here, we depict the structures of both human SS18/BRG1 and yeast SNF11/SNF2 subcomplexes. Both subcomplexes assemble into heterodimers that share a similar conformation, suggesting that SNF11 might be a homologue of SS18 in chromatin remodeling complexes. Importantly, our study shows that the self-association of the intrinsically disordered region, QPGY domain, leads to liquid-liquid phase separation (LLPS) of SS18 or SS18-SSX and the subsequent recruitment of BRG1 into phase-separated condensates. Moreover, our results show that the tyrosine residues in the QPGY domain play a decisive role in the LLPS of SS18 or SS18-SSX. Perturbations of either SS18-SSX LLPS or SS18-SSX’s binding to BRG1 impair NIH3T3 cell transformation by SS18-SSX. Our data demonstrate that both LLPS and assembling into chromatin remodelers contribute to the oncogenic activity of SS18-SSX in synovial sarcomas.
- 18 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Open AccessPhase transition and remodeling complex assembly are important for SS18-SSX oncogenic activity in synovial sarcomas
Oncoprotein SS18-SSX is a hallmark of synovial sarcomas. However, as a part of the SS18-SSX fusion protein, SS18’s function remains unclear. Here, we depict the structures of both human SS18/BRG1 and yeast SNF11/SNF2 subcomplexes. Both subcomplexes assemble into heterodimers that share a similar conformation, suggesting that SNF11 might be a homologue of SS18 in chromatin remodeling complexes. Importantly, our study shows that the self-association of the intrinsically disordered region, QPGY domain, leads to liquid-liquid phase separation (LLPS) of SS18 or SS18-SSX and the subsequent recruitment of BRG1 into phase-separated condensates. Moreover, our results show that the tyrosine residues in the QPGY domain play a decisive role in the LLPS of SS18 or SS18-SSX. Perturbations of either SS18-SSX LLPS or SS18-SSX’s binding to BRG1 impair NIH3T3 cell transformation by SS18-SSX. Our data demonstrate that both LLPS and assembling into chromatin remodelers contribute to the oncogenic activity of SS18-SSX in synovial sarcomas.